Gitnux/Report 2026

Biomedical Device Industry Statistics

The global biomedical device market is projected to reach $1.01 trillion by 2029, explore the figures behind market growth, company activity and the 2026 trend set.
309Statistics
105Sources
12Sections
1Visuals
51mRead
November 11, 2026Updated
Biomedical Device Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published ·Updated
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The biomedical device industry at a glance

North America represented 35.2% of the global market in 2025, and regional demand is shaped by rising healthcare expenditure, chronic disease prevalence and procedure volumes. The market totaled $732.0B in 2024 and is projected to reach $1,007.6B by 2029, supported by equipment, implants, disposables and surgical instruments.

$732.0B
Global market size, 2024
6.6%
Forecast CAGR, 2024–2029
35.2%[94]
North America share, 2025
25,530[2]
US registered manufacturing firms, 2025
Market size
The global medical device market totaled $732.0 billion in 2024, according to Lattice analysis. Medical equipment represented $329.4 billion, surgical implants $119.3 billion, surgical disposables $109.5 billion and surgical instruments $87.8 billion.
Forecast & CAGR
The market is projected to reach $1,007.6 billion by 2029, implying a 6.6% compound annual growth rate from 2024 to 2029. Forecast segment CAGRs range from 6.5% for medical equipment and surgical instruments to 6.8% for surgical implants and other products.
Market share & regions
North America accounted for 35.2% of the global market in 2025, followed by Europe at 26.2% and Asia-Pacific at 23.0%; Latin America and the Middle East and Africa represented 8.8% and 6.8%, respectively. MedTech Europe separately estimated Europe’s 2025 market at roughly €173 billion and 25.6% of the world market based on manufacturer prices.[94][68]
Segmentation
By product category, medical equipment was the largest segment in 2024 at $329.4 billion, followed by surgical implants at $119.3 billion, surgical disposables at $109.5 billion and surgical instruments at $87.8 billion. By device application, cardiovascular devices held a 12.5% share in 2025, ahead of diagnostic imaging at 10.2% and orthopedics at 9.6%.[94]
Key players & concentration
The industry remains fragmented across thousands of manufacturers, although large multinational companies dominate high-value categories. The FDA reported 25,530 registered device manufacturing firms in the United States in 2025 and regulated 264,670 medical devices, indicating a broad supplier base alongside substantial product-scale concentration.[2]
Pricing
European market estimates are based on manufacturer prices rather than retail or hospital reimbursement prices. MedTech Europe valued the European medical technology market at approximately €173 billion in 2025, while reporting 1.8% year-on-year growth in that year and an average annual growth rate of 5.6% over the preceding decade.[68]
Trends, drivers & challenges
Growth is supported by rising healthcare expenditure, chronic disease prevalence, procedure volumes, digital health adoption and demand for robotics and minimally invasive technologies. Key challenges include regulatory complexity, supply-chain resilience, reimbursement pressure and uneven regional growth; Europe’s market growth slowed to 1.8% in 2025 after averaging 5.6% annually over the prior decade.[68][2]
Consumer behavior & competition
Hospitals and clinicians increasingly compete on clinical outcomes, workflow efficiency, interoperability and total cost of ownership rather than device price alone. Competitive intensity is visible in the FDA’s 2025 workload: CDRH received 21,780 device submissions, authorized 124 novel medical devices and oversaw 25,530 registered manufacturing firms.[2]
M&A
M&A activity in 2026 has focused on cardiovascular, oncology, surgical robotics and dialysis technologies. Medtronic completed its $585 million CathWorks acquisition in April 2026, Olympus agreed to acquire BioProtect for $270 million in May 2026, and Enovis announced a proposed acquisition of eCential Robotics for approximately €176 million in cash consideration plus up to €35 million in contingent consideration.[29][95][96]
Regulation
In fiscal year 2025, FDA review cohorts included 3,465 510(k) decisions, 77 original PMA and panel-track submissions, and 57 De Novo decisions. CDRH also issued 21 guidances and 125 safety-related communications during calendar year 2025.[2]
Latest news
On November 3, 2026, Rockwell Medical announced an agreement to acquire Vantive’s hemodialysis concentrates, machines, water-treatment systems and related services business. The combined business is projected to generate annual revenue of $400 million to $450 million, with closing expected in mid-2027.[97]

02 Ranking

Top 10 Companies in the Biomedical Device Industry

The leading companies in the biomedical device industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Boston Scientific stands out for minimally invasive cardiovascular, digestive, urologic and neurological devices because it reports an 18% operating margin and R&D at 10.2% of revenue, while Medtronic focuses on cardiac, surgical, diabetes and neurotechnology devices since it reports an 8.4% revenue growth and a 17.8% operating margin.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in cardiac and structural heart

    Boston Scientific

    US

    Ranked #1 · 9.4 · Cardiac and structural heart

    Why we picked it: It combines multiple minimally invasive categories and reports an 18% operating margin and R&D at 10.2% of revenue.

    See in ranking ↓Visit bostonscientific.com ↗

  2. Leader in diabetes and neurotechnology

    Medtronic

    IE

    Ranked #2 · 9.1 · Diabetes and neurotechnology

    Why we picked it: It operates across 150+ countries and reports an 8.4% revenue growth and a 17.8% operating margin.

    See in ranking ↓Visit medtronic.com ↗

  3. Leader in vision care devices

    Johnson & Johnson

    US

    Ranked #3 · 9.0 · Vision care devices

    Why we picked it: Its MedTech segment covers cardiovascular, orthopaedic, surgical and vision devices, with R&D at 15.6% of revenue.

    See in ranking ↓Visit jnj.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the biomedical device industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Boston Scientific

Cardiac and structural heart · US

9.4
2

Medtronic

Diabetes and neurotechnology · IE

9.1
3

Johnson & Johnson

Vision care devices · US

9.0
4

Edwards Lifesciences

Cardiac and structural heart · US

9.0
5

Siemens Healthineers

Imaging and diagnostics · DE

8.8
6

Terumo

Vascular, cardiovascular, blood and diabetes devices · JP

8.7
7

GE HealthCare

Imaging, patient care and pharmaceutical diagnostic devices · US

8.5
8

BD

Injection, medication delivery, diagnostics and intervention devices · US

8.3
9

B. Braun

Infusion, surgery, dialysis and hospital-care devices · DE

8.3
10

ResMed

Sleep-apnea and respiratory-care devices · US

8.2

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the biomedical device industry. In Biomedical Device Industry Statistics. Gitnux. https://gitnux.org/biomedical-device-industry-statistics/#top-companies

report visual · Comparison

European medical device market share by country, based upon manufacturer prices

Germany leads with 24.6%.

Germany24.6%
United Kingdom13.7%
France12.9%
Italy12.4%
Spain9.4%
Netherlands7%
source-verifiedmedtecheurope.org

04 Statistics

Technology & Innovation

AI authorization has accumulated quickly, with more than 1,600 AI-enabled devices having FDA marketing authorization by September 2026. Automation adoption also shows unevenness: 9% reported fully integrated automation across operations in 2024.

AI in the biomedical device industry

  • 63 AI-enabled medical devices received FDA authorization decisions in 2018 in the United States.[1]
  • 26 AI-enabled medical devices received FDA authorization decisions in 2017 in the United States.[1]
  • 124 AI-enabled medical devices received FDA authorization decisions in 2021 in the United States.[1]
  • 3 AI-enabled medical devices received FDA authorization decisions in 2013 in the United States.[1]
  • 5 AI-enabled medical devices received FDA authorization decisions in 2015 in the United States.[1]
  • More than 1,600 AI-enabled medical devices had FDA marketing authorization in the United States by September 2026.[2]

Automation in the biomedical device industry

  • 34.5% of medical and life-sciences manufacturing survey respondents identified integrating automation or robotics as an investment priority in 2024.[3]
  • 9% of medical and life-sciences manufacturing survey respondents had fully integrated automation across operations in 2024.[4]
  • 31.4% of medical and life-sciences manufacturing survey respondents reported that they were not currently using automation in 2024.[3]
  • 69% of medical and life-sciences manufacturing survey respondents had implemented some form of automation in 2024.[4]

Digital Transformation in the medical devices sector (sector benchmark)

  • Across medtech companies, 36% achieved limited value and no sustainable change from digital transformation in 2021.[5]
  • Across medtech and IVD professionals worldwide, 89% said their company had implemented or planned to implement AI or digital solutions in its product range in 2020.[6]
  • Across medtech manufacturing executives, 64% highly prioritized digitizing manufacturing in a 2022 survey.[7]
  • Across medtech and IVD professionals worldwide, 87% said their company had implemented or planned to implement AI or digital solutions in regulatory or quality-management systems in 2020.[6]
  • Across medtech companies, 29% met or exceeded their digital-transformation targets with sustainable change in 2021, according to BCG’s global survey.[5]
  • Across medtech companies, 35% created value but failed to meet all digital-transformation targets in 2021.[5]

Technology Adoption in the medical devices sector (sector benchmark)

  • Among emerging medtech companies, 62% had adopted electronic trial-master-file systems, compared with 89% of enterprise and global companies in the 2025 benchmark.[8]
  • Across healthcare industrial-ecosystem SMEs in Europe, 17.3% already used robotics in 2023.[9]
  • Across healthcare industrial-ecosystem SMEs in Europe, 13.7% already used artificial intelligence in 2023.[9]
  • Across healthcare industrial-ecosystem SMEs in Europe, 8.6% already used remote patient-monitoring technologies in 2023.[9]
  • Among emerging medtech companies, 38% had adopted clinical-trial-management systems, compared with 72% of enterprise and global companies in the 2025 benchmark.[8]
  • Across healthcare industrial-ecosystem SMEs in Europe, 31.0% already used cloud technologies in 2023.[9]

Cloud Computing in the medical devices sector (sector benchmark)

  • Across surveyed medtech organizations, 31% managed all postmarket-surveillance processes with cloud-based technology in 2025.[8]
  • Across surveyed medtech organizations, 33% reported reliable enterprise-wide use of cloud-based technologies in 2025.[8]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 66% reported that 50%–74% of infrastructure was in the cloud in 2022.[10]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 21% reported that 75%–100% of infrastructure was in the cloud in 2022.[10]

Big Data in the medical devices sector (sector benchmark)

  • 45% was the average share of planned digital-enabler spending that medtech companies allocated to infrastructure, cloud enablement, architecture modernization, and AI and big data, globally, in 2021.[5]
  • 15.3% of SMEs in Europe’s healthcare industrial ecosystem had adopted big data and related data analytics, according to the 2023 EMI survey.[9]
  • Across medtech and biopharma companies surveyed in 2018, 67% of medtech firms invested in data analytics for reporting.[11]
  • Across healthcare industrial-ecosystem SMEs in Europe, 15.3% had adopted big data and related data analytics in 2023.[9]

05 Statistics

Data & Analytics

Data quality and traceability remain practical constraints in postmarket work. In 2025, 51% of medical-device companies still managed postmarket-surveillance processes and data manually or partially manually.

Business intelligence in the biomedical device industry

  • 45% of medtech regulatory respondents could determine where products were registered globally within a few minutes in 2025.[8]
  • 7% of medtech quality leaders worldwide identified insufficient training or skills to analyze or apply data as a barrier to proactive quality management in 2025.[8]
  • 17% of medtech regulatory respondents rated their data quality as excellent for AI implementation in 2025.[8]
  • 48% of medtech regulatory respondents planned to implement automated submission tracking and reporting tools in 2025.[8]
  • 14% of medtech quality leaders worldwide identified a lack of clearly defined metrics that drive value as a barrier to proactive quality management in 2025.[8]
  • 40% of medtech companies used paper or mixed paper-electronic processes for postmarket quality activities in 2025.[12]

Data analytics in the biomedical device industry

  • 15.3% of SMEs in the European healthcare industrial ecosystem had adopted big data and related data analytics by 2023.[9]
  • 61% of Lazard medical-device, diagnostics and tools respondents viewed disease diagnosis as highly susceptible to disruption by data analytics, AI and machine learning in 2023.[13]
  • 72% of medtech clinical leaders expected to invest in AI or machine-learning initiatives during the 12 months following the 2025 survey.[8]
  • 30% of medical-device corporate executives viewed robotic-assisted surgery as highly susceptible to disruption by data analytics, AI and machine learning in 2023.[13]
  • 89% of medtech organizations had not deployed AI in a meaningful way according to the 2026 Medtech CRM Benchmark.[8]
  • 48% of Lazard medical-device, diagnostics and tools respondents viewed diagnostic imaging and image-guided therapies as leading disruption areas for data analytics, AI and machine learning in 2023.[13]

Data Quality in the medical devices sector (sector benchmark)

  • 51% of medical-device companies still managed postmarket-surveillance processes and data manually or partially manually in the 2025 benchmark survey.[8]
  • 73% of medical-device professionals using literature-review software trusted their data quality, compared with 38% using spreadsheets, in a global survey; survey year not stated.[14]
  • 56% of medical-device companies used non-validated general-purpose tools for clinical data collection in the 2024 MedTech industry survey.[15]
  • 45.9% of healthcare-sector business partners identified data quality as a major challenge in managing digital product information in the 2021 survey.[16]
  • 60% of medical-device professionals using literature-review software reported data traceability, compared with 4% using spreadsheets, in a global survey; survey year not stated.[14]

Data Governance in the medical devices sector (sector benchmark)

  • 31.4% of healthcare-sector business partners had a digital-asset-management system for storing images and product data sheets in the 2021 survey.[16]
  • More than 72% of healthcare-sector business partners had not established a product-master-data system reflecting data governance in the 2021 survey.[16]
  • 62.3% of healthcare-sector business partners identified creating a central data master as a single source of truth as the greatest digital-product-information challenge in 2021.[16]
  • More than 30% of healthcare-sector business partners had no clear formal data-governance guidelines in the 2021 survey.[16]

KPIs in the biomedical device industry

  • 50% of medical-device service leaders prioritized service revenue as a key KPI or metric in 2024.[17]
  • 43% of medical-device companies identified product-testing performance as a leading quality or regulatory metric for leadership in 2023.[15]
  • 32% of medical-device companies identified design-history-file or device-master-record transfer as a leading quality or regulatory metric for leadership in 2023.[15]
  • 32% of medtech clinical organizations had established baseline KPIs in 2025.[8]
  • 6% of medtech clinical organizations had KPIs that drove critical business decisions in 2025.[8]
  • 44% of medical-device companies identified process capability or performance as a leading quality or regulatory metric for leadership in 2023.[15]

06 Statistics

Strategy & Growth

Topline growth reported for early 2026 is modest, at 7% year-over-year for US and European medtech during the first six months of 2026. Consolidation continues, including Medtronic’s $585 million CathWorks acquisition in April 2026.

Growth in the biomedical device industry

  • 7% was the year-over-year topline growth reported for US and European medtech during the first six months of 2026.[18]
  • 5.9% is the projected compound annual growth rate for the global medical-device market from 2024 to 2030.[19]
  • $7.7 billion was Johnson & Johnson’s cardiovascular-franchise sales in 2024.[20]
  • 21.4% was Johnson & Johnson’s 2024 cardiovascular-franchise sales growth, including Shockwave Medical.[20]
  • $545.38 billion was the estimated global medical-devices industry value in 2024.[21]
  • 6%–7% was the revenue-growth rate commercial medtech leaders were forecast to achieve in 2025.[18]

Differentiation in the biomedical device industry

  • 8% of sales was Medtronic’s approximate R&D intensity in the latest full fiscal year reported.[22]
  • 36% of revenue was Glaukos’s R&D intensity among companies covered in the 2025 Medtech Big 100 analysis.[23]
  • 10% was the average R&D spending as a share of revenue among Medtech Big 100 companies that disclosed the metric.[23]
  • 18% of sales was Edwards Lifesciences’ approximate R&D intensity in the latest full fiscal year reported.[22]
  • 12% of sales was Dexcom’s approximate R&D intensity in the latest full fiscal year reported.[22]
  • 11% of sales was Intuitive Surgical’s approximate R&D intensity in the latest full fiscal year reported.[22]

Mergers and acquisitions in the biomedical device industry

  • $68 billion was the 2024 medtech M&A deal value reported by Bain & Company.[24]
  • 34% was the share of 2025 year-to-date strategic medtech deal value categorized as spin-offs or divestitures.[24]
  • 33% of fiscal-2025 medical-equipment, consumables and services deals involved financial investors.[25]
  • $600 million was the upfront payment in Johnson & Johnson’s 2024 agreement to acquire V-Wave, with up to approximately $1.1 billion in potential milestones.[26]
  • 11% was the increase in average medtech M&A deal size in 2025 compared with 2024.[18]
  • 67% of fiscal-2025 medical-equipment, consumables and services deals involved industrial investors.[25]

Strategic partnerships in the biomedical device industry

  • 29% of surveyed MedTech organizations acquired startups to drive connected-health innovation in 2024.[27]
  • 20 markets had cleared Johnson & Johnson MedTech’s VELYS robotic-assisted solution by June 2024.[28]
  • 71% of surveyed MedTech organizations relied on open innovation to drive connected-health innovation in 2024.[27]
  • $100 million was the potential milestone payment Medtronic’s expanded Cosmo Pharmaceuticals collaboration could reach by the end of 2024.[29]
  • 55% of surveyed MedTech organizations invested in in-house R&D for connected-health innovation in 2024.[27]
  • 59% of surveyed MedTech organizations invested in strategic partnerships and joint ventures for connected-health innovation in 2024.[27]

07 Statistics

People & Workforce

Workforce measures show variability in retention, remote work and training time. Job postings in the U.S. medical devices and equipment subsector reached 134,553 in 2024.

Hiring in the biomedical device industry

  • 138,186 job postings were recorded for the U.S. medical devices and equipment subsector in 2023.[30]
  • 64.0% of Sonova’s internal leadership hires were women in fiscal 2023/24 globally.[31]
  • 134,553 job postings were recorded for the U.S. medical devices and equipment subsector in 2024.[30]
  • 205,155 job postings were recorded for the U.S. medical devices and equipment subsector in 2022.[30]
  • 65.3% of Sonova’s leadership hires were women in fiscal 2022/23 globally.[31]

Employee retention in the biomedical device industry

  • 5.40 years was the average tenure of Mindray’s female employees in 2025.[32]
  • 9% was STAAR Surgical’s U.S. employee turnover rate in 2023.[33]
  • 5.50 years was the average tenure of Mindray’s male employees in 2024.[32]
  • 8% was STAAR Surgical’s U.S. employee turnover rate in 2021.[33]
  • 5.22 years was the average tenure of Mindray’s female employees in 2023.[32]

Remote Work in the medical devices sector (sector benchmark)

  • Remote medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[34]
  • Remote medical device and diagnostics professionals reported a median salary of $142,000 in 2023, according to an industry salary survey.[34]
  • About 50% of medical device and diagnostics professionals worked fully remotely in 2023, based on 226 usable survey responses in the United States.[34]
  • Remote medical device and diagnostics employees worked an average of 41.5 hours per week in 2023, compared with 43 hours for office-based employees.[34]

Hybrid Work in the medical devices sector (sector benchmark)

  • Hybrid medical device and diagnostics professionals reported a median salary of $135,000 in 2023, according to an industry salary survey.[34]
  • Hybrid medical device and diagnostics professionals represented about 40% of respondents in MD+DI’s 2023 salary survey, covering 226 usable responses.[34]
  • Hybrid medical device professionals reported a median salary of $150,000 in 2026, compared with $140,000 for remote and $116,000 for in-office professionals.[34]
  • Hybrid medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[34]

Upskilling in the biomedical device industry

  • 30.50 training hours per female employee were reported by Mindray in 2025.[32]
  • 39.90 training hours per middle-management employee were reported by Mindray in 2025.[32]
  • 37.02 training hours per employee were reported by Mindray in 2023.[32]
  • 36.69 training hours per senior-management employee were reported by Mindray in 2025.[32]
  • 13 compliance-training hours per employee were reported by STAAR Surgical in 2021.[33]

Employee Engagement in the medical devices sector (sector benchmark)

  • In medical devices, 23% of employees disagreed that their total compensation was fair relative to similar roles at other companies in the 2026 benchmark.[35]
  • In medical devices, 73% of employees were engaged in benchmark data collected from July 2025 through June 2026, predominantly across Northern America, Oceania, Europe and Asia.[35]
  • Medical devices organizations had a median employee net promoter score of 14 in Culture Amp’s 2026 benchmark.[35]
  • In medical devices, 91% of employees agreed they understood how their work contributed to company goals in benchmark data collected through June 2026.[35]

DEI in the biomedical device industry

  • 44% of Medtronic’s global managers and above were women at the end of December 2024.[36]
  • 99% was Medtronic’s global gender pay-equity result in fiscal 2024.[36]
  • 41% of Medtronic’s U.S. workforce was ethnically diverse at the end of December 2024.[36]

08 Statistics

Customer & Sales

Supplier choice responds to technical support experience and service quality. In the U.S., 65% of healthcare and procurement professionals said a negative technical-support experience could make them change a medical-device supplier.

Customer experience in the biomedical device industry

  • 59% of U.S. medical-device users considered an easy-to-navigate website very important or somewhat important.[37]
  • 32% of the top 50 global medtech companies named customer experience as a strategic priority in 2025 or the first half of 2026.[38]
  • 55% of U.S. medical-device users considered easy access to health records or data very important or somewhat important.[37]
  • 18% of the top 50 global medtech companies had embedded customer experience as a formal operating priority in 2025 or the first half of 2026.[38]
  • 20% of the top 50 global medtech companies named customer experience as a strategic priority in 2023.[38]

Customer retention in the biomedical device industry

  • 15.0% of Brevard County medical-equipment users who changed suppliers cited the supplier going out of business.[39]
  • 17.2% of Polk County medical-equipment users who changed suppliers cited moving residence in the CMS follow-up survey.[39]
  • 65% of U.S. healthcare professionals and procurement professionals said a negative technical-support experience could make them change medical-device supplier.[38]
  • 24.1% of medical-equipment users in Polk County who changed suppliers cited dissatisfaction with service quality in the CMS follow-up survey.[39]
  • 20.7% of Polk County medical-equipment users who changed suppliers cited moving to a supplier listed in the Medicare Demonstration Directory.[39]

Customer acquisition in the biomedical device industry

  • 10% month-over-month growth in website visitors was the reported medtech target in the First Page Sage dataset.[40]
  • 21–34 qualified leads per month was the reported volume for midsize B2B medtech companies in the First Page Sage dataset.[40]
  • 70% of total website traffic was the reported minimum organic-share target for medtech companies in the First Page Sage dataset.[40]
  • 1,183% was the reported marketing return on investment for medtech companies in the First Page Sage dataset.[40]
  • 1.10 was the reported pay-per-click return on advertising spend for medtech companies in the First Page Sage dataset.[40]

Customer loyalty in the biomedical device industry

  • 17% was the highest-ranked importance score for a focus on value-based procurement among hospitals reporting changed manufacturer preferences in 2025.[41]
  • 21% was the highest-ranked importance score for improved customer service and support among hospitals reporting changed manufacturer preferences in 2025.[41]
  • 19% was the highest-ranked importance score for better pricing and purchase models among hospitals reporting changed manufacturer preferences in 2025.[41]
  • 69% of global hospital or medical-clinic customers said they would recommend the organization in the 2025 Qualtrics study.[42]
  • 19% was the fifth-rank importance score for enhanced technological features among hospitals reporting changed manufacturer preferences in 2025.[41]

Lead generation in the biomedical device industry

  • 10–25% was the reported medtech conference-lead conversion-rate range in the XDS attribution guide.[43]
  • 2–5% was the reported medtech email-to-sales-representative-meeting conversion-rate range in the XDS attribution guide.[43]
  • 1.6% was the reported average medical-device website lead-conversion rate in the 2025 First Page Sage industry table.[44]
  • 7,980 monthly unique sessions was the reported average traffic level for a medical-device website in the cited First Page Sage data.[44]
  • 1.8% was the reported biotech visitor-to-lead conversion rate in the cited 2025 industry table for comparison with medtech.[44]

09 Statistics

Marketing & Brand

Digital marketing effectiveness shows a wide spread in reported performance. More than 90% of surveyed medtech companies reported digital-marketing success improved by at least 10%.

Marketing in the biomedical device industry

  • 50% of U.S. medtech survey respondents reported a digital-marketing return on investment of at least 20%.[38]
  • 80% of medtech commercial organizations said they were actively interested in focusing on content personalization.[8]
  • 70% of medtech organizations used manual processes or fragmented systems to manage claims and substantiation linking.[8]
  • 65% of medtech companies surveyed five years before 2021 spent no more than 20% of their marketing budgets on digital marketing.[38]
  • 74% of EU5 medtech companies surveyed had shifted more budget toward digital marketing by 2020.[38]

Digital marketing in the biomedical device industry

  • 80% of surveyed medtech commercial leaders were actively interested in content personalization.[8]
  • 31% of medtech organizations had a centralized digital-asset-management system available to all marketers.[8]
  • More than 90% of surveyed medtech companies reported that digital-marketing success had improved by at least 10%.[38]
  • 56% of surveyed medtech leaders ranked speed to market among the leading improvement priorities for commercial content.[8]
  • 60% of medtech organizations using manual or homegrown content systems needed more than four weeks for review and approval.[8]

Branding in the biomedical device industry

  • $2.926 billion was Danaher’s medical-devices brand value in 2024.[45]
  • $5.532 billion was Abbott’s medical-devices brand value in 2024.[45]
  • $4.430 billion was Siemens Healthineers’ medical-devices brand value in 2024.[45]
  • 33% was Unity Lab Services’ increase in medical-devices brand value between 2023 and 2024.[46]
  • $7.684 billion was Fresenius’s medical-devices brand value in 2024, the highest in Brand Finance’s ranking.[45]

Social media in the biomedical device industry

  • 2.5% was the average reply rate to LinkedIn connection notes sent by medical-device accounts from May 2025 through April 2026.[47]
  • 63,946 LinkedIn connection requests were sent by medical-device accounts in the May 2025–April 2026 benchmark.[47]
  • 55 medical-device accounts generated the LinkedIn outreach benchmark covering May 2025 through April 2026.[47]
  • 263 leading medical-device organizations were analyzed for employee social-media activity in a DSMN8 study.[48]
  • 8.9% was the average reply rate to follow-up LinkedIn messages after connection acceptance for medical-device accounts.[47]

Influencer Marketing in the medical devices sector (sector benchmark)

  • 8.57 million influencer posts about the health industry were published globally in 2023, across the platforms measured by Sprout Social.[49]
  • 10% of healthcare and pharmaceutical marketers reported that they did not invest in creator or influencer marketing in 2026.[50]
  • 29% of healthcare and pharmaceutical marketers had dedicated but flat budgets for creator or influencer marketing in 2026.[50]
  • 50% of healthcare and pharmaceutical marketers had dedicated, growing budgets for creator or influencer marketing in 2026.[50]
  • 8% of healthcare and pharmaceutical marketers had dedicated but shrinking budgets for creator or influencer marketing in 2026.[50]

10 Statistics

Operations & Execution

Execution constraints concentrate around regulatory complexity and scaling while maintaining quality. In 2025, 42.4% cited regulatory challenges as the biggest barrier to commercializing medical products.

Process optimization in the biomedical device industry

  • 42.4% of medical and life sciences manufacturing respondents cited regulatory challenges as the biggest barrier to commercializing medical products in 2025.[3]
  • 63% of U.S. medical device manufacturers planned to automate material handling processes in the 2024 capital-spending survey.[51]
  • 9% of medical and life sciences manufacturing respondents had fully integrated automation across their operations in 2025.[4]
  • 46% of healthcare and medical-device organizations were developing manufacturing-automation capabilities in-house in 2026.[51]
  • 75% of U.S. medical device manufacturers planned to automate assembly processes in the 2024 capital-spending survey.[51]

Operational efficiency in the biomedical device industry

  • 9% of surveyed medical-device and diagnostics organizations had a manufacturing-execution system fully implemented at all facilities in 2022.[7]
  • 17.8% of medical and life sciences manufacturing respondents identified scaling up while maintaining quality as the biggest commercialization obstacle in 2025.[3]
  • 28% of medical-device organizations surveyed had MES or digital manufacturing technology only partially implemented in 2025.[7]
  • 27.3% of medical and life sciences manufacturing respondents identified reducing or managing production costs as the biggest commercialization obstacle in 2025.[3]
  • 64% of medtech and life-sciences manufacturing executives highly prioritized manufacturing digitization in a 2022 survey.[7]

Quality management in the biomedical device industry

  • 28% of U.S. medical-device units affected by recalls in 2024 were linked to parts-related failure.[52]
  • 1,059 U.S. medical-device recall events occurred in 2024.[52]
  • 440.4 million medical-device units were recalled in the United States in 2024.[52]
  • 9% of U.S. medical-device recalls from fiscal years 2020 through 2024 were Class I recalls.[53]
  • 8.6% was the increase in U.S. medical-device recall events from 2023 to 2024.[52]

Supply chain in the biomedical device industry

  • 48% of European hospital pharmacists reporting medical-device shortages in 2023 cited shortages or discontinuations of device components, parts or accessories.[54]
  • $886.6 billion was the projected global medical-device market value for 2032 in the federal shortage landscape analysis.[55]
  • $542.2 billion was the projected global medical-device market value for 2024 in the federal shortage landscape analysis.[55]
  • 658 European hospital pharmacists cited supply-chain problems in the 2023 medical-device shortage survey.[54]
  • 12.3% of medical and life sciences manufacturing respondents identified supply-chain reliability as their biggest production-line change challenge in 2025.[3]

Outsourcing / Offshoring in the medical devices sector (sector benchmark)

  • 335 U.S. medical device contract manufacturers were identified in 2022, up from 314 in the prior registry.[56]
  • $81.5 billion was the global medtech outsourcing market in 2023, covering contract development and manufacturing organizations (CDMOs).[56]
  • $26.3 billion was the U.S. medtech CDMO market in 2023, after 12.9% growth from 2022.[56]
  • More than half of 59 global medtech CDMO transactions in 2023 had cross-border characteristics.[56]
  • $18.5 billion was the European medtech CDMO market in 2023.[56]

11 Statistics

Finance & Pricing

Pricing pressure remains measurable through Medicare. A ten-year Medicare price decrease applied to certain U.S. medical-device types studied, at 61%.

Pricing strategy in the biomedical device industry

  • 61% was the ten-year Medicare price decrease for certain medical-device types studied in the United States.[57]
  • 3.5 times greater net price increase was realized by medium-sized medical technology companies than by other size groups in the 2024 benchmark.[58]
  • 44.8% was the price reduction produced by Medicare competitive bidding for 12 durable medical devices in the United States.[57]
  • 71.3% of Swiss medical-device-sector survey respondents reported increased product costs linked to MDR/IVDR requirements in 2024.[59]
  • 58.8% of Swiss medical-device-sector survey respondents reported increasing their own product prices because of MDR/IVDR and other cost increases in 2024.[59]

Cost reduction in the biomedical device industry

  • $193 million were Baxter’s restructuring and business-optimization costs in 2022, including manufacturing and supply-chain changes.[60]
  • $174 million were Baxter’s restructuring and business-optimization costs in 2023, including initiatives to simplify and streamline operations.[60]
  • $162 million were Baxter’s restructuring and business-optimization costs in 2024, including initiatives to reduce its healthcare cost structure.[60]
  • $45 million to $51 million was Teleflex’s expected cost savings from restructuring programs between 2023 and 2025.[60]
  • $144 million of Abbott’s 2023 restructuring charges supported cost reduction and efficiency initiatives in medical devices, diagnostics and pharmaceuticals.[60]

Profitability in the biomedical device industry

  • 4.9% was the 2024 operating-profit margin of the Precision Devices segment at a diversified medical-technology company.[60]
  • 43.6% was the 2024 adjusted EBITDA margin of the MedTech and Specialty Audio segment at a diversified medical-technology company.[60]
  • 59.5% was Danaher’s 2024 gross-profit margin from continuing operations.[60]
  • $5.3 billion was Danaher’s 2024 free cash flow from continuing operations.[60]
  • 53.9% was AngioDynamics’ consolidated gross margin in the fiscal year ended May 31, 2025.[60]

Financial planning in the biomedical device industry

  • $370 million was total in-house R&D expenditure by Canada’s medical-device manufacturing sector in 2023.[61]
  • $3.703 billion was Johnson & Johnson MedTech’s 2024 research-and-development expense.[60]
  • $7.7 billion was Johnson & Johnson’s 2024 Cardiovascular franchise sales, including Shockwave Medical.[60]
  • $5.309 billion was Danaher’s 2024 free cash flow from continuing operations after capital expenditures and disposals.[60]
  • $77.542 billion was Danaher’s total assets at December 31, 2024.[60]

12 Statistics

Product & Service

Service and recalls add workload, with recall termination timing varying by class. The average time from initiation to termination for completed Class III recalls in U.S. fiscal years 2020–2024 was 396 business days.

Product development in the biomedical device industry

  • 56 510(k), 31 PMA and 1 De Novo predetermined-change-control plans were authorized by FDA in fiscal year 2025.[2]
  • 4,202 pre-submissions were recorded by FDA in fiscal year 2024, covering medical-device development discussions before formal submissions.[2]
  • $52.1 million was the estimated total development cost for a therapeutic complex medical device in 2018 dollars in the United States.[55]
  • 18.0% was the modeled reduction in development costs from using adaptive clinical-study designs for therapeutic complex medical devices.[55]
  • 22.4% was the modeled reduction in development costs from improvements in FDA review efficiency and interactions for therapeutic complex medical devices.[55]

Product lifecycle in the biomedical device industry

  • 632 business days was the average time from initiation to termination for completed Class I recalls initiated in U.S. fiscal years 2020–2024.[62]
  • 28% of units affected by U.S. medical-device recalls in 2024 were associated with parts-related failures.[52]
  • 74% of U.S. medical-device recalls in fiscal years 2020–2024 exceeded FDA’s three-month termination policy after manufacturers requested termination.[53]
  • 396 business days was the average time from initiation to termination for completed Class III recalls initiated in U.S. fiscal years 2020–2024.[62]
  • 3,934 medical-device recalls were initiated in U.S. fiscal years 2020–2024.[53]

After-sales in the biomedical device industry

  • 68% of magnetic-resonance units using outside service providers were covered by full-service contracts in IMV’s 2020 survey.[63]
  • 11% of installed magnetic-resonance systems received primary service support from in-house teams in IMV’s 2020 survey.[63]
  • 2% of installed magnetic-resonance systems received primary service support from non-OEM magnetic-resonance manufacturers in IMV’s 2020 survey.[63]
  • Nearly 1 in 4 follow-up medical-device service visits were associated with ineffective preventive maintenance in Aquant’s 2025 benchmark.[64]
  • 83% was the first-visit resolution rate for the best medical-device service teams in Aquant’s 2025 benchmark.[64]

Value proposition in the biomedical device industry

  • $1.69 billion in additional U.S. economic output was generated for every $1 billion in advanced-medical-technology revenue, according to AdvaMed.[65]
  • 61% was the decrease over 10 years in Medicare prices for the medical-device types studied by NBER researchers.[57]
  • 869 PMA and HDE device applications had been approved by FDA’s CDRH and CBER from fiscal year 2008 through fiscal year 2024.[2]
  • 4,528,153 initial medical-device reports were submitted by manufacturers to FDA’s MAUDE database between September 2019 and December 2022.[66]
  • 16.4% of initial medical-device reports for devices without an ongoing recall were submitted late to FDA between September 2019 and December 2022.[66]

13 Statistics

Sustainability & Ethics

Decarbonization efforts show large internal targets while industry estimates emphasize material and extraction. Siemens Healthineers reported a 49% reduction in Scope 1 and 2 emissions from 2019 to fiscal 2025.

Sustainability in the biomedical device industry

  • 89% of Siemens Healthineers’ site electricity came from renewable sources in fiscal 2024 globally.[67]
  • 25 countries representing more than 80% of Siemens Healthineers’ workforce held Great Place to Work certification in 2024.[67]
  • 5–10% of medical-technology emissions are associated with packaging, according to a 2026 global sector estimate.[68]
  • 25–30% of potential medical-technology emissions abatement faces economic or regulatory barriers, according to a 2026 global sector estimate.[68]
  • 45–55% of medical-technology emissions arise from raw-material extraction and processing, according to a 2026 global sector estimate.[68]

ESG in the biomedical device industry

  • 30% of Siemens Healthineers’ senior-management roles were held by women in fiscal 2024 globally.[67]
  • 4.5% was Siemens Healthineers’ reduction in global Scope 3 emissions from 2019 to fiscal 2025.[67]
  • 49% was Siemens Healthineers’ reduction in global Scope 1 and 2 emissions from 2019 to fiscal 2025.[67]
  • 90% is Siemens Healthineers’ target reduction for Scope 1 and 2 emissions by 2030 from its 2019 baseline.[67]
  • 28% is Siemens Healthineers’ target reduction for Scope 3 emissions by 2030 from its 2019 baseline.[67]

Ethics in the biomedical device industry

  • 72.7% of smaller surgical randomized controlled trials reported a conflict-of-interest statement, compared with 89.8% of trials enrolling more than 100 participants.[69]
  • 97% of medical-device clinical investigations detailed ethical or institutional review-board approval in the later period of a decade-long international review.[70]
  • 47% of medical-device clinical investigations included a sample-size justification in the later period of a decade-long international review.[70]
  • 59.0% of the 600 most-cited clinical trials published from 2019 to 2022 had at least one author with industry affiliation internationally.[71]
  • 20.9% of 444 surgical randomized controlled trials involving medical devices disclosed conflicts of interest during 1985–2014 internationally.[70]

CSR in the biomedical device industry

  • 989 employees worked for Medtronic Limited in the United Kingdom in reporting year 2024.[36]
  • 259 field-based vehicles were operated by Medtronic Limited in the United Kingdom in reporting year 2024.[36]
  • 30% of Siemens Healthineers’ senior-management positions were held by women in fiscal 2024.[67]
  • 3.3 billion patient touchpoints is Siemens Healthineers’ 2030 global target for access to healthcare.[67]
  • More than 30 organizations contributed to the CHARME medical-technology decarbonization roadmap supported by BD in 2023.[72]

Circular economy in the biomedical device industry

  • $495,520,878 in savings was reported by AMDR members’ reprocessed-device customers for 2025.[73]
  • 30–50% lower costs were reported for reprocessed single-use devices compared with virgin devices in the 2025 AMDR survey.[73]
  • 56,707,926 kilograms of carbon-dioxide emissions were avoided through AMDR-member reprocessed devices in 2025.[73]
  • 73% of European medical devices with electronic components were single-use in a cited study.[74]
  • 69 tons of carbon dioxide were reduced annually through natural-gas savings at a Siemens Healthineers clinical-laboratory site.[67]

Carbon footprint in the biomedical device industry

  • 50% is the maximum carbon-dioxide savings reported in a cited life-cycle study for recycling and remanufacturing medical catheters.[5]
  • Around 1% of global emissions is the estimated carbon footprint of the medical-technology sector in 2026.[68]
  • 0.07 tonnes of carbon-dioxide equivalent came from incinerated operational waste at Medtronic Limited in the United Kingdom in 2024.[36]
  • 1,449.24 tonnes of carbon-dioxide equivalent came from air travel by Medtronic Limited employees in the United Kingdom in 2024.[36]
  • 4.5% of worldwide greenhouse-gas emissions are associated with healthcare, with medtech products contributing about one-third of healthcare emissions.[5]

15 Statistics

Globalization & Expansion

Cross-border trade relies on distribution reach and regulation readiness. The distribution network covered more than 140 countries and regions globally in 2025 for one cited distribution network.

Globalization in the biomedical device industry

  • India imported medical devices worth ₹137,088 crore in fiscal year 2024–25.[85]
  • 86.1% of Thailand’s medical-device export value came from single-use devices in 2025.[86]
  • 18.0% of global medical-device imports were accounted for by the United States in 2025, followed by Germany at 8.0%.[86]
  • €4 billion was Europe’s medical-device trade surplus in 2025, with the United States, China, Japan and Mexico remaining its main trade partners.[68]
  • 82.6% of Thailand’s medical-device import value came from single-use and technology-intensive durable devices in 2025.[86]

Cultural adaptation in the biomedical device industry

  • 34% of medical-device regulatory-survey respondents identified bolstering resources and recruitment as a key lesson from the previous year.[87]
  • 65% of medical-device regulatory-survey respondents found translations challenging to manage in 2024.[87]
  • 54% of medical-device regulatory-survey respondents cited getting packaging and labeling text right as a challenge in 2024.[87]
  • 35% of medical-device regulatory-survey respondents said greater investment in company culture was a key lesson from the previous year.[87]
  • 59% of medical-device regulatory-survey respondents had difficulty managing tables in packaging and labeling in 2024.[87]

Supplier management in the biomedical device industry

  • 73 suppliers were reported by Meihua International Medical Technologies in its 2024 annual report.[88]
  • The three largest suppliers represented 31.92% of Meihua International Medical Technologies’ purchases in 2024.[88]
  • US$2.4 million of Utah Medical Products’ 2024 sales came from its largest overseas distributor in China.[60]
  • 13.73% of Meihua International Medical Technologies’ 2024 purchases came from its largest reported supplier.[88]
  • 9.05% of Meihua International Medical Technologies’ 2024 purchases came from its third-largest reported supplier.[88]

Stakeholder management in the biomedical device industry

  • 123 patients were separately surveyed by the Medical Device Innovation Consortium on patient engagement in clinical trials.[81]
  • 76% of surveyed physicians reported that knowing a device met FDA approval standards substantially influenced prescribing decisions.[89]
  • 75.5% of respondents in a 2024 European real-world-evidence stakeholder survey identified data privacy as a concern.[90]
  • 57% of surveyed physicians reported clinical resources such as UpToDate substantially influenced their prescribing decisions.[89]
  • 53 device and diagnostic industry stakeholders were surveyed by the Medical Device Innovation Consortium on patient engagement in clinical trials.[81]

Distribution channels in the biomedical device industry

  • The company’s distribution network covered more than 140 countries and regions globally in 2025.[91]
  • $3.1 million of Baird Medical’s 2024 hospital sales were direct, compared with $16.8 million through deliverers and $17.2 million through distributors.[92]
  • 2,538 domestic distributors contributed revenue to the same Chinese medical-device company in 2023.[91]
  • DiaSorin uses a network of more than 200 independent distributors in countries where it has no direct presence.[93]
  • 934 overseas distributors contributed revenue to the Chinese medical-device company covered by the 2026 Hong Kong filing in 2025.[91]

Key questions about the biomedical device industry

What is the current scale of the biomedical device market?
The global biomedical device market was valued at approximately $732.0 billion in 2024 and is projected to reach $1.01 trillion by 2029.
How fast is the market growing through the forecast window?
The forecast CAGR for 2024–2029 is 6.6%, with the market projected to reach $1,007.6 billion by 2029.
Which companies lead the biomedical device industry?
Boston Scientific stands out for minimally invasive cardiovascular, digestive, urologic and neurological devices because it reports an 18% operating margin and R&D at 10.2% of revenue, while Medtronic focuses on cardiac, surgical, diabetes and neurotechnology devices since it reports an 8.4% revenue growth and a 17.8% operating margin.
What technology shifts are most visible in FDA authorization activity and manufacturing adoption?
More than 1,600 AI-enabled medical devices had FDA marketing authorization in the United States by September 2026, and 9% reported fully integrated automation across operations in 2024.
How fragmented is the supplier base versus product-scale concentration?
The industry is fragmented across thousands of manufacturers, while large multinational companies dominate high-value categories. In the United States, the FDA reported 25,530 registered device manufacturing firms in 2025.
What does the FDA regulatory workload indicate about innovation throughput?
In fiscal year 2025, CDRH received 21,780 device submissions, authorized 124 novel medical devices, and oversaw 25,530 registered manufacturing firms.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Biomedical Device Industry Statistics. Gitnux. https://gitnux.org/biomedical-device-industry-statistics
MLA
Samuel Norberg. "Biomedical Device Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/biomedical-device-industry-statistics.
Chicago
Samuel Norberg. 2026. "Biomedical Device Industry Statistics." Gitnux. https://gitnux.org/biomedical-device-industry-statistics.

Sources & references

105 sources cited across this report

  1. hhs.gov
  2. fda.gov
  3. go.ascentialtech.com
  4. ascentialmls.com
  5. bcg.com
  6. nsf.org
  7. mastercontrol.com
  8. veeva.com
  9. monitor-industrial-ecosystems.ec.europa.eu
  10. pages.awscloud.com
  11. www-statista-com.libproxy.pcc.edu
  12. explore.veeva.com
  13. lazard.com
  14. distillersr.com
  15. blog.greenlight.guru
  16. sana-suisse-med.ch
  17. truecontext.com
  18. ey.com
  19. ustlfsci.hkust.edu.hk
  20. financialfilings.com
  21. go.frost.com
  22. asfreeman.com
  23. medicaldesignandoutsourcing.com
  24. argaamplus.s3.amazonaws.com
  25. translinkcf.com
  26. investor.jnj.com
  27. capgemini.com
  28. jnj.com
  29. news.medtronic.com
  30. ohiolifesciences.org
  31. report.sonova.com
  32. scribd.com
  33. responsibilityreports.com
  34. mddionline.com
  35. cultureamp.com
  36. medtronic.com
  37. c1.sfdcstatic.com
  38. mckinsey.com
  39. cms.gov
  40. firstpagesage.com
  41. namsa.com
  42. qualtrics.com
  43. blog.madebyxds.com
  44. octoagency.io
  45. brandirectory.com
  46. static.brandirectory.com
  47. expandi.io
  48. linkedin.com
  49. media.sproutsocial.com
  50. brand-news.it
  51. assemblymag.com
  52. ul.com
  53. files.gao.gov
  54. oecd.org
  55. aspe.hhs.gov
  56. alirahealth.com
  57. nber.org
  58. revenueml.com
  59. rosapeak.com
  60. sec.gov
  61. www150.statcan.gc.ca
  62. gao.gov
  63. imvinfo.com
  64. discover.aquant.ai
  65. advamed.org
  66. bmj.com
  67. siemens-healthineers.com
  68. medtecheurope.org
  69. academic.oup.com
  70. pmc.ncbi.nlm.nih.gov
  71. doi.org
  72. bd.com
  73. amdr.org
  74. ce-hub.org
  75. health.ec.europa.eu
  76. op.europa.eu
  77. validation.gmp-compliance.org
  78. greenlight.guru
  79. cognition.us
  80. runsafesecurity.com
  81. mdic.org
  82. deloitte.com
  83. dennemeyer.com
  84. 2bridge.partners
  85. pib.gov.in
  86. krungsri.com
  87. schlafenderhase.com
  88. cdn.yahoofinance.com
  89. journals.sagepub.com
  90. pubmed.ncbi.nlm.nih.gov
  91. www1.hkexnews.hk
  92. stocktitan.net
  93. en.wikipedia.org
  94. sebi.gov.in
  95. olympus-europa.com
  96. ir.enovis.com
  97. ir.rockwellmed.com
  98. bostonscientific.com
  99. edwards.com
  100. terumo.com
  101. gehealthcare.com
  102. bbraun.com
  103. who.int
  104. desapublications.un.org
  105. olympus-global.com